Welcome to our dedicated page for Travere Therapeutics SEC filings (Ticker: TVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Travere Therapeutics, Inc. (TVTX) provides access to the company’s official disclosures as a Nasdaq‑listed biopharmaceutical issuer focused on rare kidney, liver and metabolic diseases. Travere files periodic and current reports with the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934.
Recent Form 8‑K filings document press releases announcing quarterly and preliminary annual financial results, including net product sales and other financial metrics, as well as broader corporate updates. These reports specify when information is being furnished rather than filed for purposes of Section 18 of the Exchange Act and clarify that such information is not automatically incorporated by reference into registration statements unless expressly stated.
Travere also uses Form 8‑K to report material regulatory developments. For example, the company has filed 8‑Ks describing FDA communications on the supplemental New Drug Application (sNDA) for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS), including the decision that an advisory committee meeting was no longer needed and confirmation of the Prescription Drug User Fee Act (PDUFA) target action date. Another 8‑K notes the FDA’s extension of the review timeline after the company submitted additional information characterized as a Major Amendment.
Through this page, users can review Travere’s financial reporting (10‑K and 10‑Q when available), current reports on significant events (8‑K), and other disclosures that describe the company’s clinical programs, commercial activities, risk factors and capital structure. Stock Titan enhances these filings with AI‑powered summaries that highlight key points in lengthy documents, helping readers quickly understand topics such as revenue drivers, R&D spending, regulatory interactions and forward‑looking statements. Real‑time updates from EDGAR and access to insider and executive transaction reports, when filed on forms such as Form 4, allow investors to monitor how management actions and regulatory events intersect with Travere’s strategy in rare diseases.
Travere Therapeutics, Inc. Chief Research Officer William E. Rote reported an open-market sale of 9,100 shares of common stock at $39.09 per share. After this transaction, he directly holds 113,987 shares. The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan and includes shares sold to cover tax obligations from vesting performance restricted stock units.
William E. Rote submitted a Form 144 notice reporting proposed sale of 9,100 shares of Common Stock tied to restricted stock vesting on 04/13/2026. The filing also records that 12,446 shares were sold on 02/03/2026 for $409,100.02. The securities are listed on NASDAQ.
Travere Therapeutics director Gary A. Lyons exercised stock options and sold shares on the same day. He exercised options for 8,000 shares of Common Stock at an exercise price of $16.3300 per share, then sold 8,000 shares at $41.0700 per share.
The sale was carried out under a pre-arranged Rule 10b5-1(c) trading plan adopted on November 11, 2025, and involved shares underlying options expiring on May 18, 2026. Following these transactions, he directly holds 57,500 shares of Travere Therapeutics Common Stock.
Travere Therapeutics director Roy D. Baynes exercised stock options and sold shares in a planned transaction. He exercised options covering 32,750 shares of common stock at exercise prices between $15.43 and $21.38 per share, then sold 32,750 shares in open-market trades at $41.07 and $42.12 per share under a Rule 10b5-1 trading plan adopted on November 17, 2025. After these transactions, he directly owned 37,500 shares of Travere Therapeutics common stock.
Travere Therapeutics SVP and Chief Accounting Officer Sandra Calvin reported an option exercise and share sale. On April 14, 2026, she exercised employee stock options covering 15,250 shares of common stock at exercise prices of $22.40, $8.93, and $20.46 per share. She then sold 21,977 shares of common stock at $41.07 per share in an open-market transaction made under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2025. After these transactions, she directly held 42,353 shares of Travere Therapeutics common stock.
Travere Therapeutics, Inc. chief commercial officer Peter Heerma reported a grant of 14,000 shares of common stock and a related share sale. The 14,000-share award on April 13, 2026 reflects settlement of performance restricted stock units tied to FDA approval of FILSPARI in FSGS. On April 14, 2026, he sold 7,215 shares at an average price of $41.9288 solely to cover tax withholding on the vested units under the company’s equity incentive plan. Following these transactions, he directly holds 138,608 shares of Travere common stock.
Travere Therapeutics Chief Research Officer William E. Rote reported receiving 14,000 shares of common stock as an equity award. The shares were acquired at no cost and are tied to performance restricted stock units granted on January 31, 2025.
According to the disclosure, these PSUs vested on April 13, 2026 after Travere confirmed that the U.S. Food and Drug Administration approved FILSPARI (sparsentan) for FSGS. Following this vesting and share issuance, Rote directly holds 123,087 shares of Travere Therapeutics common stock, reflecting both this award and his existing stake.
Travere Therapeutics, Inc. director and CEO Eric M. Dube reported a PSU vesting and related share sales. On April 13, 2026, he acquired 64,000 shares of common stock at no cost through vested performance restricted stock units, triggered by FDA approval of FILSPARI (sparsentan) in FSGS.
On April 15, 2026, he sold 56,815 shares at a weighted average price of $41.01, 7,165 shares at a weighted average price of $41.75, and 20 shares at $42.66, all in open-market transactions under a Rule 10b5-1 trading plan that also covered tax obligations from the PSU vesting. Following these transactions, he directly holds 432,886 shares of Travere common stock, the same level as before the grant and sales.
Travere Therapeutics, Inc.’s Chief Legal Officer and General Counsel Elizabeth E. Reed exercised employee stock options and sold shares of common stock in a series of transactions. She exercised options to acquire 37,500 shares at exercise prices of $19.08, $17.96, and $15.46 per share and also received 14,000 shares as a grant or award.
Ms. Reed then sold a total of 51,500 shares of common stock in open-market and related transactions at weighted average prices around $41–$43 per share, leaving her with 105,211 shares owned directly after the transactions. Footnotes state that certain sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025 and that part of the sales were mandatory “sell to cover” trades to satisfy tax withholding obligations.
The 14,000-share award reflects performance restricted stock units granted on January 31, 2025 that vested on April 13, 2026 after the U.S. Food and Drug Administration approved FILSPARI (sparsentan) in FSGS.
Travere Therapeutics’ chief financial officer, Christopher R. Cline, reported a mix of equity compensation and share sales in Travere Therapeutics, Inc. common stock. He received 14,000 shares on April 13, 2026 as a grant tied to performance restricted stock units that vested after the U.S. Food and Drug Administration approved FILSPARI (sparsentan) for FSGS.
Between April 13 and 15, 2026, he sold a total of 8,327 shares in open-market transactions at prices ranging from about $28.85 to $42.61. Footnotes explain that part of these sales were mandated “sell to cover” transactions to satisfy tax withholding on vested restricted and performance stock units, and others were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025. After these transactions, he directly holds 116,899 shares of Travere common stock.